HarlanAndrewPintoMD

Oncology • Stanford, CA

Associate Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Pinto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pinto's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1991
Massachusetts General HospitalResidency, Internal Medicine, 1983 - 1986
Yale School of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1988 - 2026
OH State Medical License 1986 - 1988
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Start of enrollment: 1995 May 30
Completed
Phase 2
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 1996 Jun 01
Completed
Phase 2
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers Start of enrollment: 1998 Sep 01
Recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
ACTIVE_NOT_RECRUITING
PHASE3
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis.
Vishesh Khanna, Gohar Eslami, Rochelle Reyes, Robert Diep, Sebastian Fernandez-Pol
NPJ Precision Oncology. 2025-02-03
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.
A Dimitrios Colevas, Anthony J Cmelak, David G Pfister, Sharon Spencer, Douglas Adkins
Journal of the National Comprehensive Cancer Network. 2025-02-01
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (...
M Margaret Kemeny, Fengmin Zhao, Arlene A Forastiere, Paul Catalano, Stanley R Hamilton
Annals of Surgical Oncology. 2023-02-01

Grant Support

Exploiting Tumor Hypoxia--Does IT Work ClinicallyNational Cancer Institute1996–2000